Zeo ScientifiX, Inc.

Zeo ScientifiX, Inc. is a clinical-stage biopharmaceutical firm that develops and manufactures biological therapies for regenerative medicine, degenerative conditions, and topical aesthetic uses. The company creates proprietary therapeutics from ethically sourced birth tissues, such as amniotic fluid and Wharton's jelly, as well as autologous patient blood. Its primary offerings include Zofin, an amniotic fluid-derived biologic containing extracellular vesicles and nanoparticles, and Patient Pure X, a blood-derived autologous treatment for pain and musculoskeletal conditions. The company also supplies topical aesthetic formulations. It distributes these biologics and associated services primarily to healthcare providers, including physicians, clinics, and medical practices that administer cellular treatments to patients.

The company maintains its executive headquarters and an extracellular vesicle processing laboratory in Davie, Florida, where it conducts research, development, and manufacturing. Its commercial operations rely on an internal team of five sales professionals alongside third-party distributors. The business serves a customer base located across the United States and internationally.

Summary of the business section of Zeo ScientifiX's latest annual report, written by StockData.

“As of June 30, 2026, we had 33 full-time employees and no part-time employees.”